Bri2 Protein Inhibits Aβ Peptide Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for Alzheimer's disease and related dementias, such as familial British and Danish dementias, are inadequate in preventing the aggregation of Aβ-peptide into amyloid fibrils and the formation of amyloid plaques, which are central to the diseases' pathology.
Innovation Solution
The use of isolated proteins comprising residues 90-236 of Bri2 and its Brichos domain from various species, which have been found to decrease amyloid fibril formation and aggregation of Aβ-peptide, offering a new treatment option for these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic approaches are used, then treatment of Alzheimer's disease is provided, but aggregation of Aβ-peptide into amyloid fibrils is not prevented
Solution Approach 1:
The patent introduces Bri2 protein as an intermediary substance that mediates between Aβ-peptide and the cellular environment. Bri2 acts as a molecular chaperone that binds to Aβ-peptide and prevents its aggregation into amyloid fibrils, thereby resolving the contradiction between providing treatment and preventing harmful aggregation.
Solution Approach 2:
The patent converts the harmful aggregation process into a beneficial protective mechanism by using Bri2 protein to bind Aβ-peptide in a way that prevents toxic aggregate formation. The same binding interaction that could lead to aggregation is instead harnessed to protect against aggregation, transforming the potential harm into therapeutic benefit.
2Quantity of substance
If Aβ-peptide is produced by processing of APP, then amyloid plaques are formed, but the reasons for processing are incompletely understood
Solution Approach 1:
The patent utilizes the natural self-processing of APP to produce Aβ-peptide, and then employs Bri2 protein to self-regulate the subsequent aggregation process. The system leverages the existing biological processing pathway without requiring external intervention to stop Aβ production, instead using Bri2 to automatically prevent the harmful consequences of this production.
3Object-generated harmful factors
If Bri2 protein is used to prevent Aβ aggregation, then amyloid fibril formation is decreased, but new therapeutic approach complexity is introduced
Solution Approach 1:
The patent uses recombinant Bri2 protein that can be produced in large quantities through standardized molecular biology techniques. This allows the therapeutic approach to be replicated and standardized across different production systems, reducing the practical complexity despite the novel mechanism of action.
Data Source
AI summary
An isolated protein is provided for use in treatment of a condition selected from the group consisting of Alzheimer's disease, familial Danish dementia and familial British dementia in a mammal, including man. The isolated protein is selected from the group consisting of proteins comprising an amino acid sequence having at least 70% identity to residues 90-236 of Bri2 from human; and proteins comprising an amino acid sequence having at least 70% identity to any one of the Brichos domains of Bri2 from human, chimpanzee, bovine, pig, mouse and rat.